Company Description
NeOnc Technologies (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes.
As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain.
These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer.
Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain.
NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.
NeOnc has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid which is administered to brain cancer patients via intranasal delivery.
We are currently conducting a Phase 2a trial with recurrent malignant glioma patients. Our second lead product, NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol, has been authorized to proceed to clinical testing in cancer patients.
We have designed a Phase 1/2 trial for oral NEO212, set to begin in late 2023. In this trial, NEO212 will be administered orally to patients with primary and secondary brain tumors.
Furthermore, NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, etc.), but has not yet been studied in human patients.
| Country | United States |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Thomas C. Chen |
Contact Details
Address: 8335 Sunset Boulevard, Suite 240 Los Angeles, CA 90069 United States | |
| Phone | (310) 663-7831 |
| Website | neonctech.com |
Stock Details
| Ticker Symbol | NTHI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001979414 |
| Employer ID | 92-1954864 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas C. Chen, M.D., Ph.D. | Chief Executive Officer and Chairman |
| Patrick Walters | Chief Operating Officer |
| Keithly Garnett | Chief Financial Officer and Director |
| Amir Heshmatpour | Executive Chairman and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 1, 2024 | FWP | Free Writing Prospectus |
| Mar 1, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 23, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 5, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 16, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 18, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 27, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Aug 9, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 5, 2023 | D | Notice of Exempt Offering of Securities |
| Jun 22, 2023 | DRS | [Cover] Draft Registration Statement |